Discovery of 4-morpholino-pyrimidin-6-one and 4-morpholino-pyrimidin-2-one-containing Phosphoinositide 3-kinase (PI3K) p110β isoform inhibitors through structure-based fragment optimisation
The discovery of 4-morpholino-pyrimidin-6-one and 4-morpholino-pyrimidin-2-one-containing inhibitors of Phosphoinositide 3-kinases (PI3K) p110 beta isoform is reported. Structure-based optimisation of the original fragment hit resulted in lead compounds with improvements in ligand efficiency, lipophilicity efficiency, p110 beta potency and selectivity over p110 alpha. (C) 2012 Elsevier Ltd. All rights reserved.
[EN] HETEROARYL INHIBITORS OF PLASMA KALLIKREIN<br/>[FR] INHIBITEURS HÉTÉROARYLE DE LA KALLICRÉINE PLASMATIQUE
申请人:SHIRE HUMAN GENETIC THERAPIES
公开号:WO2022197758A1
公开(公告)日:2022-09-22
The present invention provides compounds and compositions thereof which are useful as inhibitors of plasma kallikrein and which exhibit desirable characteristics for the same.